Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Cholesterol Lowering in Prostate Cancer
NCT06437574Phase 2Recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jul 2024
- Primary completion
- Feb 2028
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 2 trial of Vytorin, ezetimibe in prostate cancer (PCa), sponsored by Cedars-Sinai Medical Center. Started Jul 2024; status: recruiting.
02
Drugs
Vytorinezetimibe
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06437574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437574.